Taiwan's Y.F. Chemical faces further sanctions from the country's food and drug authority, which has ordered it to pull all sodium chloride solution products and keep production shut after contamination was found to cause adverse reactions in at least a dozen patients, Xinhua reported.
Over the weekend, China's leadership took the time to focus again on ensuring the quality of consumer goods with an underlying message for the medical device and drug industries highlighted by recent probes of top officials.
Medtronic, known mostly for its high-priced medical devices, is looking for some deals in China as it chases low-price customers for its line of "value products."
Will it get the results it wants? India's drug regulator plans to test 42,000 domestic-made drugs throughout the rest of this year to prove their quality and shake the notion that the nation's drugs are not safe or are of low quality.
One area in which the "Make in India" government effort may need to highlight further is the stents used by the nation's hospitals. Nearly half were made at home last year.
Moscow is opening a gray market to allow imports of drugs intended for sale in other countries to be sold in Russia without the consent of the maker with a trademark for the product. The government hopes the move will lower pharmaceutical costs.
Cipla and Wockhardt each announced drug recalls from the U.S. market, the former because of failure to meet specifications, the latter because of U.S. FDA concerns about two of its India plants. A Japan devicemaker also announced a U.S. recall.
Medicago is building a $200 million manufacturing facility in Quebec City, where it will use plant technology to produce vaccines against Ebola and other viruses.
China and Russia have become new targets for compulsory-licensing campaigns as an activist group widens its global challenge to Gilead's expensive Sovaldi (sofosbuvir) hepatitis C drug.
China, the country of 5-year plans, has inaugurated a longer one: 10 years for increased manufacturing, including biomedicine and high-end medical devices. The State Council calls it "Made in China 2025."